COVID-19: Vaccines and Therapeutics
The Centers for Disease Control and Prevention today released updated guidance for clinicians treating COVID-19 in patients who received the Pfizer COVID-19 antiviral pill Paxlovid.
Pfizer’s COVID-19 vaccine booster for children under age 5 was 80.3% effective and well tolerated in a clinical trial.
The FDA Tuesday authorized a single booster dose for children in this age group.
The U.S. Postal Service has delivered about 350 million free at-home tests to households since January. On December 15, 2022, the Biden Administration announced its COVID-19 Winter Preparedness Plan. As part of this plan, free COVID-19 tests are once again available through www.COVIDTests.gov.
FDA today authorized a single booster dose for children 5-11 who completed the Pfizer vaccine primary series at least five months before.
FDA yesterday approved using baricitinib to treat COVID-19 in certain hospitalized adults, and warned not to use a Skippack Medical Lab test.
FDA issues updates on a COVID-19 monoclonal antibody and antiviral pill, and certain Fresenius Medical Care hemodialysis machines.
The guidance is intended to help state policymakers identify and address related issues during and after the public health emergency.
Based on an updated analysis, FDA said the risk of thrombosis with thrombocytopenia syndrome warrants limiting the vaccine to certain adults.
This webinar rural hospital executives and board leaders discuss how boards can work with all levels within their communities.